GSK Agrees to $3B Settlement

In the largest fraud settlement in U.S. history, GlaxoSmithKline has agreed to pay $3 billion in settlements and to plead guilty to criminal charges related to its branding, safety disclosures and price reporting of several drugs.

The Justice Department on Monday announced a “global settlement” that resolves three investigations related to the pharmaceutical giant.

The company will pay $1.8 billion to resolve criminal and civil liabilities for off-label marketing, including $757 million in criminal fines for misbranding antidepressants Paxil and Wellbutrin, and more than $1 billion for alleged False Claims Act violations related to payments of kickbacks for those and other drugs.


Comments (0) Trackbacks (0)

No comments yet.

Leave a comment

No trackbacks yet.